532 related articles for article (PubMed ID: 33964223)
1. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo MS; Natama MH; Somé A; Traoré O; Rouamba T; Bellamy D; Yameogo P; Valia D; Tegneri M; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Orindi B; Ramos Lopez F; Flaxman A; Cappuccini F; Kailath R; Elias S; Mukhopadhyay E; Noe A; Cairns M; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
Lancet; 2021 May; 397(10287):1809-1818. PubMed ID: 33964223
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Datoo MS; Natama HM; Somé A; Bellamy D; Traoré O; Rouamba T; Tahita MC; Ido NFA; Yameogo P; Valia D; Millogo A; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Ramos-Lopez F; Cairns M; Provstgaard-Morys S; Aboagye J; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
Lancet Infect Dis; 2022 Dec; 22(12):1728-1736. PubMed ID: 36087586
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS; Dicko A; Tinto H; Ouédraogo JB; Hamaluba M; Olotu A; Beaumont E; Ramos Lopez F; Natama HM; Weston S; Chemba M; Compaore YD; Issiaka D; Salou D; Some AM; Omenda S; Lawrie A; Bejon P; Rao H; Chandramohan D; Roberts R; Bharati S; Stockdale L; Gairola S; Greenwood BM; Ewer KJ; Bradley J; Kulkarni PS; Shaligram U; Hill AVS;
Lancet; 2024 Feb; 403(10426):533-544. PubMed ID: 38310910
[TBL] [Abstract][Full Text] [Related]
4. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
[TBL] [Abstract][Full Text] [Related]
5. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N; Topazian HM; Natama HM; Bellamy D; Traoré O; Somé MA; Rouamba T; Tahita MC; Bonko MDA; Sourabié A; Sorgho H; Stockdale L; Provstgaard-Morys S; Aboagye J; Woods D; Rapi K; Datoo MS; Lopez FR; Charles GD; McCain K; Ouedraogo JB; Hamaluba M; Olotu A; Dicko A; Tinto H; Hill AVS; Ewer KJ; Ghani AC; Winskill P
Lancet Infect Dis; 2024 May; 24(5):465-475. PubMed ID: 38342107
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ
Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191
[TBL] [Abstract][Full Text] [Related]
9. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
Silk SE; Kalinga WF; Salkeld J; Mtaka IM; Ahmed S; Milando F; Diouf A; Bundi CK; Balige N; Hassan O; Mkindi CG; Rwezaula S; Athumani T; Mswata S; Lilolime NS; Simon B; Msami H; Mohamed M; David DM; Mohammed L; Nyaulingo G; Mwalimu B; Juma O; Mwamlima TG; Sasamalo IA; Mkumbange RP; Kamage JJ; Barrett JR; King LDW; Hou MM; Pulido D; Carnrot C; Lawrie AM; Cowan RE; Nugent FL; Roberts R; Cho JS; Long CA; Nielsen CM; Miura K; Draper SJ; Olotu AI; Minassian AM
Lancet Infect Dis; 2024 Jun; ():. PubMed ID: 38880111
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Olotu A; Lusingu J; Leach A; Lievens M; Vekemans J; Msham S; Lang T; Gould J; Dubois MC; Jongert E; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Lapierre D; Ballou WR; Cohen J; Lemnge MM; Peshu N; Marsh K; Riley EM; von Seidlein L; Bejon P
Lancet Infect Dis; 2011 Feb; 11(2):102-9. PubMed ID: 21237715
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
RTS,S Clinical Trials Partnership
Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
16. Seasonal vaccination with RTS,S/AS01
Dicko A; Ouedraogo JB; Zongo I; Sagara I; Cairns M; Yerbanga RS; Issiaka D; Zoungrana C; Sidibe Y; Tapily A; Nikièma F; Sompougdou F; Sanogo K; Kaya M; Yalcouye H; Dicko OM; Diarra M; Diarra K; Thera I; Haro A; Sienou AA; Traore S; Mahamar A; Dolo A; Kuepfer I; Snell P; Grant J; Webster J; Milligan P; Lee C; Ockenhouse C; Ofori-Anyinam O; Tinto H; Djimde A; Chandramohan D; Greenwood B
Lancet Infect Dis; 2024 Jan; 24(1):75-86. PubMed ID: 37625434
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
Sirima SB; Tiono AB; Ouédraogo A; Diarra A; Ouédraogo AL; Yaro JB; Ouédraogo E; Gansané A; Bougouma EC; Konaté AT; Kaboré Y; Traoré A; Chilengi R; Soulama I; Luty AJ; Druilhe P; Cousens S; Nébié I
PLoS One; 2009 Oct; 4(10):e7549. PubMed ID: 19855847
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE
Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112
[TBL] [Abstract][Full Text] [Related]
19. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
